Cargando…

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oñate, Guadalupe, Pratcorona, Marta, Garrido, Ana, Artigas-Baleri, Alicia, Bataller, Alex, Tormo, Mar, Arnan, Montserrat, Vives, Susana, Coll, Rosa, Salamero, Olga, Vall-Llovera, Ferran, Sampol, Antònia, Garcia, Antoni, Cervera, Marta, Avila, Sara Garcia, Bargay, Joan, Ortín, Xavier, Nomdedéu, Josep F., Esteve, Jordi, Sierra, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162955/ https://www.ncbi.nlm.nih.gov/pubmed/37147301 http://dx.doi.org/10.1038/s41408-023-00839-1

Ejemplares similares

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
por: Oñate, Guadalupe, et al.
Publicado: (2022)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia
por: Díaz-Beyá, M, et al.
Publicado: (2015)

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature
por: Díaz-Beyá, Marina, et al.
Publicado: (2015)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
por: Cabezón, Marta, et al.
Publicado: (2018)

Ultrastructural, cytogenetic, and molecular findings in mast cell leukemia: Case report
por: Bosch‐Vilaseca, Anna, et al.
Publicado: (2019)

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
por: Cabezón, M., et al.
Publicado: (2021)

XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells
por: Moreno-Martínez, Daniel, et al.
Publicado: (2014)

Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells
por: Cornet-Masana, Josep Maria, et al.
Publicado: (2016)

Bone marrow fibrosis, sequence variant of asxl1, and Sjögren syndrome: A case report
por: Santaliestra, Marta, et al.
Publicado: (2020)

A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
por: Ribera, Josep‐Maria, et al.
Publicado: (2020)

Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma
por: Nomdedeu, Meritxell, et al.
Publicado: (2015)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
por: Barba, Pere, et al.
Publicado: (2022)

The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome
por: Hinai, Adil S.A. Al, et al.
Publicado: (2019)

Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience
por: García-Recio, Marta, et al.
Publicado: (2017)

PB1923: NON-HEMATOLOGIC AUTOIMMUNE DISORDERS IN CLL: PREVALENCE AND PROGNOSTIC IMPACT IN A REAL-LIFE COHORT FROM A SINGLE-CENTRE
por: De Tomás, Miguel Argüello, et al.
Publicado: (2023)

The evolution of hematopoietic cells under cancer therapy
por: Pich, Oriol, et al.
Publicado: (2021)

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
por: Genescà, E., et al.
Publicado: (2018)

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: Riera, Pau, et al.
Publicado: (2020)

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
por: Montesinos, Pau, et al.
Publicado: (2023)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
por: Martínez-Cuadrón, David, et al.
Publicado: (2022)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors
por: Roloff, Gregory W., et al.
Publicado: (2023)

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
por: González-Gil, Celia, et al.
Publicado: (2022)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe
por: Cornago, M, et al.
Publicado: (2014)

Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers
por: Arranz, Maria J., et al.
Publicado: (2022)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016)

Increase in Bloodstream Infection Due to Vancomycin-Susceptible Enterococcus faecium in Cancer Patients: Risk Factors, Molecular Epidemiology and Outcomes
por: Gudiol, Carlota, et al.
Publicado: (2013)

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2021)

Prognostic Role of the Red Blood Cell Distribution Width (RDW) in Hodgkin Lymphoma
por: Herraez, Ines, et al.
Publicado: (2020)

P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL
por: Maria Ribera, Josep, et al.
Publicado: (2023)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Influence of Sports Participation on the Behaviors of Customers of Sports Services: Linear and Qualitative Comparative Analysis Models
por: García-Pascual, Fernando, et al.
Publicado: (2023)

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
por: Cueto, Francisco J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mudi6u0i3b0j89qfmf5r6eruob